Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center

Articles

Unmet Needs and Looking Ahead in Essential Thrombocythemia

April 21st 2021

Unmet needs and current areas that are being studied in in essential thrombocythemia.

The Treatment Spectrum in Essential Thrombocythemia

April 21st 2021

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea. 

Essential Thrombocythemia: An Overview

April 14th 2021

Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.

Ongoing Unmet Needs and New Approaches in Myelofibrosis

April 14th 2021

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

A Review of Pacritinib and PACIFICA Data

April 7th 2021

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

The Role of Transplant in Myelofibrosis

April 7th 2021

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

COMFORT Data and Ruxolitinib in Myelofibrosis

March 31st 2021

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

A Look at Fedratinib and the JAKARTA Trials

March 31st 2021

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice. 

Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.